Skip to main content

For clinicians These tools display published RCT evidence to support independent clinician review -- not to replace it. Every output links to its source PMID. This platform is educational; all clinical decisions remain with the treating healthcare professional.

Evidence Based Longevity (EBL) Back to Evidence Engine
Member tier · preview , Medication and Lab Monitor is a Member-tier feature. Below is a live preview.
Learn about Pro →
Terminal 06
Open to everyone during launch

Medication and
Lab Monitor.

Each lab draw you enter is kept with its date, so a retest shows which markers moved and by how much. The history stays on your own device. When your labs change, it is ready for the conversation with your prescriber.

The medication-review workflow

Four phases. Your prescriber decides.

EBL provides the monitoring framework and evidence. Your physician makes every clinical decision. This is the firewall that keeps everyone safe.

01
Baseline capture
What are you on? What do your labs say today?

Current medications and doses go on the Physician Discussion Sheet, and the most recent lab report goes in the lab history on this page. That first draw is the starting point every later draw is read against. This is your "before" picture.

Medication entry Lab entry NNT Number needed to treat: how many people must receive a treatment for one of them to benefit, compared with the control group. context
02
Intervention layer
Grade A or B interventions on the same pathway

The Smart Retest Guide lists the evidence-graded supplements and lifestyle interventions by the biomarkers A measurable sign in the body, such as a blood test value, used to track a condition or the effect of a treatment. they were studied on, each with its letter for that use, its PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed., the trial size and the effect the trial measured.

Pathway matching PMID-cited Grade A or B only
03
Biomarker trajectory
Retest at 12 weeks. Did the interventions move the markers?

Each retest goes in the lab history. The table shows every draw by date and how each marker moved: baseline → 12 weeks → 24 weeks. If LDL-C Low-density lipoprotein cholesterol, the cholesterol fraction most closely tied to plaque in the arteries. dropped from 142 to 98 after adding omega-3 and exercise, that record is what your prescriber will want to see. If the markers did not move, the record shows that too.

Multi-visit tracking Change between draws 12-week cadence
04
Physician discussion sheet
Summary page plus citations, for the 15-minute conversation

The Physician Discussion Sheet prints current medications and supplements with their grades, PMIDs and NNT context, and the lipid values from any draw sent to it from the lab history. The full lab history downloads as a spreadsheet to bring alongside it. The sheet never says "stop" or "replace." It presents data.

Printable PMID-cited Prescriber-ready
Your own labs · stored on this device only

Your lab history.

Each lab report can be added as it comes back. Every draw is kept with its date, and the table shows how each marker moved from one draw to the next and from the first to the latest. The history stays in this browser. EBL never receives it.

The lab history needs JavaScript turned on in this browser.

Live example · interactive

A statin patient's 24-week journey.

PT
Example patient
58 years · primary prevention · no prior CVD
SIMULATED DATA
Medication
Atorvastatin 20mg
NNT (primary)
104 over 5 years
Target markers
LDL-C, ApoB Apolipoprotein B, a protein carried once on each cholesterol particle that can enter the artery wall, so it counts those particles directly., hsCRP High-sensitivity C-reactive protein, a blood marker of low-grade inflammation.
Depletions A fall in a nutrient's level caused by a medication, for example through reduced absorption or increased loss. found
CoQ10, D3, Selenium
Intervention stack added at week 0
A
Omega-3 high-dose icosapent ethyl 4 g/day
REDUCE-IT · PMID: 30415628
B
CoQ10 (ubiquinone, as in Q-SYMBIO) 100 mg three times daily
Q-SYMBIO · PMID: 25282031
B
Resistance training 2–3×/week
Resting blood pressure · PMID: 37491419
Biomarker trajectory · 24 weeks
Baseline
12 weeks
24 weeks
Auto-generated output
Physician discussion sheet
Medication and Lab Discussion · Prepared via Evidence Based Longevity
Current Rx: Atorvastatin 20mg daily (48 months)
Indication: Primary prevention · No prior CVD events
NNT context: 104 patients treated for 5 years to prevent one MI (primary prevention)
Biomarker trajectory:
LDL-C: 142 → 118 → 98 mg/dL (−31% over 24 weeks)
ApoB: 128 → 108 → 89 mg/dL (−30%)
hsCRP: 2.8 → 1.9 → 1.1 mg/L (−61%)
Concurrent interventions (PMID-cited):
• Omega-3 high-dose icosapent ethyl 4 g/day. PMID: 30415628, Grade A. Mixed EPA+DHA at 1 g/day for primary prevention is Grade D (PMID 30415637)
• CoQ10 (ubiquinone, as in Q-SYMBIO) 100 mg three times daily. PMID: 25282031, Grade B
• Resistance training 2–3×/week. Grade B for resting blood pressure (PMID 37491419); Grade A for strength and muscle size (PMID 32740889). Not graded for LDL: resistance training alone did not lower it in the pooled trials (PMID 39331324)
Based on sustained biomarker improvements across two retest intervals, the patient wishes to discuss these results with their prescriber. This report is informational only and does not constitute a recommendation to change, reduce, or discontinue any medication.

What this is. What this is not.

This tool is
✓A biomarker monitoring framework that tracks the same markers your medications target
✓An evidence library of Grade A or B supplements that target the same pathways. With PMIDs
✓A trajectory tracker that plots your labs across retest intervals (12, 24, 36 weeks)
✓A physician discussion sheet generator, PMID-cited, one page of summary plus references, designed for a 15-minute visit
✓A medication-review support tool, giving your physician the data to make the decision
This tool is not
✗A substitute for your prescribing physician's clinical judgment
✗A recommendation to stop, reduce, or change any medication
✗A claim that supplements can replace prescription medications
✗Medical advice, diagnosis, or treatment of any kind
✗A guarantee that biomarker improvements will lead to dose changes, that decision belongs to your physician alone

Supported medication pathways

Where biomarker monitoring supports the conversation.

Statins
NNT 104 (primary) · 19 (secondary)
Targets: LDL-C, ApoB, hsCRP, triglycerides
On EBL: the medication’s depletion record and the trials behind it
Metformin
NNT 14 (complications)
Targets: HbA1c A blood test that reflects average blood sugar over the previous two to three months., fasting glucose, HOMA-IR
On EBL: the medication’s depletion record and the trials behind it
PPIs
NNT 26 (GI bleed prevention)
Targets: GERD symptom score, esophageal pH
On EBL: the medication’s depletion record and the trials behind it
Antihypertensives
NNT 27 (CV event prevention)
Targets: Systolic BP, diastolic BP, MAP
On EBL: the medication’s depletion record and the trials behind it
SSRIs
NNT 7 (severe) · 14 (mild-moderate)
Targets: PHQ-9 score, GAD-7, sleep quality
On EBL: the medication’s depletion record and the trials behind it
Sleep aids
Studied mostly as short-term use
Targets: Sleep onset latency, WASO, sleep efficiency
On EBL: the medication’s depletion record and the trials behind it

Step 01 is where the sequence begins.

The lab history above works on its own. The full sequence starts with the medication check: medication check → evidence finder → biomarker baseline → retest.

Audit my medications, Step 01 →

Free during launch · No account · Your lab history stays on this device

The Medication and Lab Monitor is an educational biomarker monitoring tool. It does not prescribe, deprescribe, or recommend medication changes. All dose adjustments require approval from your prescribing physician. Evidence Based Longevity is not a medical practice and does not provide medical advice. Supplements are not substitutes for prescription medications. Stopping or reducing a medication belongs under clinical supervision. Full disclosure →